Certara (CERT)
(Real Time Quote from BATS)
$17.22 USD
+0.11 (0.64%)
Updated May 1, 2024 12:54 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Certara, Inc. (CERT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$19.06 | $23.00 | $15.50 | 11.40% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Certara, Inc. comes to $19.06. The forecasts range from a low of $15.50 to a high of $23.00. The average price target represents an increase of 11.4% from the last closing price of $17.11.
Analyst Price Targets (9 )
Broker Rating
Certara, Inc. currently has an average brokerage recommendation (ABR) of 2.45 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 2.64 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, three are Strong Buy, representing 27.27% of all recommendations. A month ago, Strong Buy represented 18.18%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 2 | 2 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 8 | 8 | 9 | 8 | 7 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.45 | 2.45 | 2.64 | 2.60 | 2.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/10/2024 | KeyBanc Capital Markets | Scott Schoenhaus | Strong Buy | Strong Buy |
4/4/2024 | JMP Securities | Constantine Kyriakos Davides | Not Available | Hold |
2/26/2024 | SVB Securities | Michael Cherny | Not Available | Hold |
12/1/2023 | Robert W. Baird & Co. | Joe Vruwink | Hold | Hold |
11/9/2023 | William Blair | Maxwell A Smock | Hold | Hold |
10/11/2023 | Stephens | Jeffrey Garro | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.45 |
ABR (Last week) | 2.45 |
# of Recs in ABR | 11 |
Average Target Price | $19.06 |
LT Growth Rate | 33.70% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 73 of 252 |
Current Quarter EPS Est: | 0.10 |